Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | LHCGR | P22888 | 1/20 | 0.36 |
| ▸ | HTRA1 | Q92743 | 4/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | MC3R | P41968 | 1/20 | 0.35 |
| ▸ | MC1R | Q01726 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.34 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4045247 | 0.93 | CTSK (0.52) | CTSKCTSSLHCGRMC4RMC3R | |
| SCHEMBL6213366 | 0.93 | CTSK (0.42) | CTSKCTSSCTSLHTRA1MC4R | |
| SCHEMBL4038592 | 0.90 | CTSK (0.52) | CTSKCTSSCTSL | |
| SCHEMBL4038989 | 0.89 | CTSK (0.51) | CTSKCTSSMC4RMC3RMC1R | |
| SCHEMBL4045091 | 0.88 | CTSK (0.61) | CTSKCTSSCTSLLHCGRMC4R | |
| SCHEMBL4044816 | 0.88 | CTSK (0.65) | CTSKCTSSCTSLPLA2G1BATG4B | |
| SCHEMBL4041845 | 0.88 | CTSK (0.50) | CTSKCTSSHTRA1MC4RMC3R | |
| SCHEMBL4038140 | 0.88 | CTSK (0.50) | CTSKCTSSCTSLLHCGRHTRA1 | |
| SCHEMBL4044651 | 0.88 | CTSK (0.50) | CTSKCTSSCTSLMC4RMC3R | |
| SCHEMBL4040427 | 0.88 | CTSK (0.54) | CTSKCTSSCTSLHTRA1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| EP-2076503-A2 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-07-08 | — | — | EP | disclosed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007136116-A2 | C-PHENYL GLYCITOL COMPOUND FOR THE TREATMENT OF DIABETES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-11-29 | — | — | WO | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885CTSS 3/4885CTSL 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.